Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study - Summary - MDSpire
Advertisement
Usefulness of indigo carmine chromoendoscopy for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy (INDIGO study): protocol for a prospective multicentre observational study
To evaluate the usefulness of indigo carmine spraying for detecting gastric cancer and gastric adenoma during upper gastrointestinal endoscopy in patients at high risk of gastric cancer.
Approach:
Study Design: Prospective multicentre observational study involving over 30 institutions.
Patient Inclusion: Patients aged 20-95 undergoing upper gastrointestinal endoscopy for surveillance or pretreatment screening will be enrolled.
Observation Method: Two-step gastric observation: first with white light imaging, followed by a second-pass observation after indigo carmine spraying.
Primary Endpoint: Proportion of patients with gastric cancer or adenoma detected during the second-pass observation.
Statistical Analysis: One-sided binomial test (α=0.05) to compare detection rate with a predefined threshold of 1.0%.
Key Findings:
Robust evidence supporting the effectiveness of indigo carmine chromoendoscopy in improving gastric cancer detection rates is limited.
Interpretation:
If successful, indigo carmine spraying may provide a simple screening strategy for early gastric cancer detection.
Limitations:
Lack of consensus on routine endoscopic techniques across different platforms.
Exclusion of patients with a history of oesophageal or gastric surgery.
Conclusion:
The study aims to determine if indigo carmine spraying increases detection rates of gastric cancer and adenomas.
A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone recovery at 18 months after treatment interruption.